How daraxonrasib tamed ‘undruggable’ pancreatic cancer

For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible. However, that narrative is rapidly changing with a new drug that can shut down the key protein that drives pancreatic cancer, nearly doubling survival rates for patients with advanced stages of the disease.